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Abstract
Background: Minor and mild-major depression are highly prevalent in primary care. There is
insufficient evidence for the effectiveness of antidepressants in the treatment of minor and mild-
major depression. We compared the effectiveness of usual primary care treatment, with or without
antidepressants, in minor and mild-major depression.
Methods: A pragmatic patient-randomized equivalence trial with 52 weeks follow-up was
conducted in The Netherlands. In total, 59 primary care physicians (PCPs) recruited and treated
181 adult patients with minor or mild-major depression. Patients were randomized to four
consultations within 3 months of usual care plus antidepressants (UCandAD) or usual care alone
(UCnoAD). The Montgomery Åsberg Depression Rating Scale (MADRS) was used to assess
changes in severity of depressive symptoms. The predefined equivalence margin was set at five
points. Multilevel analysis was used to analyze the data. Secondary outcome measures were the
Short-Form 36 (SF-36), and the Client Satisfaction Questionnaire (CSQ-8).
Results: Patients received on average 3.0 (SD 1.4) 15-min consultations within 3 months with (n
= 85) or without paroxetine (n = 96). Equivalence of UCandAD and UCnoAD was demonstrated
in the intention-to-treat analyses as well as the per-protocol analysis after 6 weeks, but not at 13,
26 and 52 weeks follow-up. No statistical differences in effectiveness between treatment groups
were found in the intention-to-treat analysis. No differences in the physical and mental functioning
(SF-36) were found between the treatment groups. Patients allocated to UCandAD were slightly
more satisfied with their treatment at 13 weeks follow-up (but not at 52 weeks follow-up) than
patients allocated to UCnoAD. Preliminary analyses suggested that subgroups such as patients with
mild-major (instead of a minor) depression might benefit from antidepressant treatment. Patients
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BMC Medicine 2007, 5:36 http://www.biomedcentral.com/1741-7015/5/36who were assigned to their preferred treatment (in particular to UCnoAD) were more often
compliant and had better clinical outcomes.
Conclusion: UCandAD was as effective as UCnoAD over the first 6 weeks, but not at 13, 26, and
52 weeks. However, superiority of either treatment could not be demonstrated either. The
question whether antidepressants add any clinical effect to usual care remains unresolved. We
recommend future studies to look for subgroups of patients who may benefit from antidepressants.
Trial registration: Dutch Trial Registry ISRCN03007807.
Background
In primary care, minor and mild-major depressions are
more common than severe major depressive disorders [1].
The estimated point prevalence of minor depression
among primary care patients varies between 3.4% and
4.7% [1]. There is insufficient evidence for the effective-
ness of antidepressants in the treatment of minor and
mild-major depression in primary care [2-7]. Potential
hazards of antidepressants are stigmatization, medicaliza-
tion, dependence, and undesirable side effects. In general,
antidepressants are only recommended when depressive
symptoms are persistent and patients experience severe
functional impairment [2,7-9]. In minor depression, spe-
cific treatments may not be indicated as there are high
rates of improvement with watchful waiting [10].
It is interesting that, from an international perspective, the
same body of scientific evidence on the treatment of
minor and mild major depression has been interpreted
differently. British guidelines favor some restraint in the
prescription of antidepressants [5,6], while the American
guidelines favor the use of these medications [11]. Dutch
depression guidelines, like the British guidelines, recom-
mend refraining from the prescription of antidepressants
in patients with minor or mild-major depression [12].
However, the prescription rate of antidepressants
increases year by year [13] and it seems that a substantial
portion of the antidepressants is prescribed to this group
[8,9]. In our opinion, prescription of antidepressants in
patients with minor or mild-major depression would only
be justified if antidepressants are shown to have addi-
tional benefits over non-pharmacological care alone.
The primary aim of the present study was to examine
whether antidepressant medication (UCandAD) adds any
clinical effectiveness to non-pharmacological usual care
(UCnoAD) by the primary care physician (PCP) in
patients with minor or mild-major depression. As we
hypothesized that antidepressants would have no addi-
tional effects in comparison with usual care, we designed
an equivalence trial.
Methods
Design
We conducted a randomized controlled trial in which
adult primary care patients with minor or mild-major
depression were randomized to receive either usual care
plus 3 months of antidepressant treatment (UCandAD) or
usual care alone (UCnoAD). Because we were interested
in the treatment effectiveness in everyday practice, we
decided to conduct a pragmatic trial, implying that the
interventions were provided by PCPs to typical primary
care patients under normal practice circumstances. UCan-
dAD was our treatment of interest, the experimental treat-
ment. We did not want to compare antidepressant
medication with placebo medication as such a treatment
is not a feasible alternative to medication in daily practice.
Instead, our control intervention, usual care, was based on
the guideline on depression issued by the Dutch College
of General Practitioners [12]. We hypothesized that
UCandAD was as effective as, i.e. equivalent to, UCnoAD.
Therefore, we designed an equivalence trial. The investiga-
tion was carried out in accordance with the latest version
of the Declaration of Helsinki [14]. The Medical Ethical
Committee of the VU University Medical Center approved
the study design.
Participants
The study was conducted in 2002 and 2003. PCPs in the
west and middle of The Netherlands were invited to par-
ticipate in this trial. During a practice visit the PCPs were
informed about the study's aim and procedures. Partici-
pating PCPs recruited, diagnosed, and treated consecutive
eligible patients themselves. Patients were considered eli-
gible if they had been diagnosed by their PCP as suffering
from a current episode of minor or mild-major depression
(i.e. three to six out of nine DSM-IV symptoms of depres-
sion, including at least one of the core symptoms, 'sad-
ness' or 'loss of pleasure'). In accordance with the Dutch
guideline on depression we defined minor depression as
a depressive disorder with three to four DSM-IV depres-
sive symptoms [12]. Largely in accordance with the Diag-
nostic and Statistical Manual of Mental Disorders, 4th
edition (DSM-IV [15]), we defined mild-major depression
as a depressive disorder with five to six symptoms. The
symptoms had to be present nearly every day for at least 2Page 2 of 11
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tress or impairment in social, occupational or other
important areas of functioning.
Patients were excluded from the trial for the following rea-
sons: age under 18 years, currently on antidepressant
medication, currently receiving psychological therapy,
experiencing psychotic features, addiction to alcohol or
drugs, loss of a loved one or significant other in the past 6
months, pregnancy or breastfeeding, inability to complete
questionnaires because of language difficulties, illiteracy
or cognitive decline, or not having a telephone.
When the PCP considered a patient to be eligible for the
study, a research assistant made an appointment for a
baseline interview at the patient's home. At the start of the
interview, the patient received a full explanation of the
study and written informed consent was obtained.
Randomization
Patients were randomly assigned to one of the treatment
conditions. Block randomization (block size 4) was used
to ensure equal numbers of patients in the two conditions
per PCP. Allocation schemes were generated by random
number tables before the trial started. After the baseline
interview with the patient, staff not in contact with the
patient opened the appropriate opaque sealed envelope.
PCPs and patients were not informed about the allocated
treatment until the first treatment session. Due to the
nature of the study, blinding of patients, research assist-
ants or PCPs was not possible.
Interventions
Before the start of the trial, PCPs received a 3-h training
session to improve recognition of patients with minor and
mild-major depression, to make a standardized DSM-IV
depression diagnosis, and to refresh their treatment skills.
All patients were scheduled for four 10–20 min consulta-
tions with the PCP at 2, 4, 7, and 11 weeks after inclusion.
During these consultations, patients randomized to the
usual care condition (UCnoAD) received patient educa-
tion, information about depression and its prognosis, and
advice on how to deal with depression (focus on the
present, maintain social activities and daily routines, exer-
cise, putting achievable goals, and restrain alcohol usage).
This treatment may be considered as a standardized form
of usual PCP care. Patients in this condition were not to
receive any antidepressant medication.
Patients randomized to the antidepressant condition
(UCandAD) received the selective serotonin reuptake
inhibitor (SSRI) paroxetine beside the usual care treat-
ment described above. The paroxetine dose was 20 mg/
day for at least 3 months, along with education about the
effects and side-effects of paroxetine. After 4 weeks the
dose could be increased to 40 mg/day in case of poor clin-
ical response. In case of intolerance to paroxetine, sertra-
line was advised. Paroxetine was chosen as first choice
antidepressant because it was the most commonly pre-
scribed antidepressant drug in The Netherlands at the
time the study started [13], and no clinically meaningful
differences between antidepressants are found in primary
care patients [16].
In both conditions, prescription of benzodiazepines was
allowed in patients with severe sleeping disturbances.
After 3 months, treatment could end or continue in the
way PCPs and patients preferred.
In equivalence trials, it is important to optimize the con-
trast between the two treatment conditions to assure a
conservative approach. Therefore, we gave PCPs some
instructions on how to shape both treatments in such a
way that the two interventions would differ mostly with
respect to the use of antidepressants. During the first 3
months, PCPs were asked to give patients in both condi-
tions the same number of consultations and not to deviate
from the medication protocol unless the PCP judged this
to be imperative. To prevent contamination from co-inter-
ventions, PCPs were asked to refrain from referral to spe-
cialized mental health care (e.g. to a psychiatrist,
psychologist, psychotherapist, or a social worker).
Assessments
Sociodemographic and clinical information was collected
at baseline, comprising the List of Threatening Experi-
ences Questionnaire (LTE-Q [17]), neuroticism (a sub-
scale of the NEO-FFI [18]), duration and history of
depressive symptoms, and chronic somatic diseases. As a
check of the diagnoses of the PCP, but without conse-
quences for the inclusion in the study, standardized psy-
chiatric diagnoses according to DSM-IV criteria were
obtained with the Composite International Diagnostic
Interview (CIDI [19]). In addition, we collected both
patients' and PCPs' treatment preferences before rand-
omization.
Primary outcome measure
The Montgomery Åsberg Depression Rating Scale
(MADRS [20], observer rating scale, 10 items, scale range
0–60, higher scores indicating more severe depressive
symptoms) was used to assess changes in severity of
depressive symptoms over 52 weeks of follow-up. The
MADRS was administered face-to-face at baseline, and by
telephone at 6, 13, 26, and 52 weeks follow-up by the
same research assistant. No differences in the mode of
administration of the MADRS (i.e. by telephone versus
face-to-face) were found [21].Page 3 of 11
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The Short-Form 36 (SF-36 [22,23]) was completed by
patients during the baseline interview and was sent to the
patients' home at 6, 13, and 52 weeks follow-up. The SF-
36 is a self-report quality of life measure, consisting of
eight scales that are aggregated into two summary meas-
ures: the Physical (PCS) and Mental (MCS) Component
Summary scores. Lower scores indicate worse health,
higher scores indicate better health.
The Client Satisfaction Questionnaire (CSQ-8 [24], self-
report scale, eight items, item range 1–4, higher scores
indicating higher satisfaction with the treatment received)
was sent to the patients' home at 13 and 52 weeks follow-
up.
Regarding the secondary outcomes we were only inter-
ested in possible differences between treatment groups,
and thus not in demonstrating equivalence.
Equivalence margins
The equivalence margin for improvement in MADRS
score was set at five points. A five-point difference in
MADRS score corresponds to 0.5 standard deviation of
the MADRS change score (mean 12.5; SD 10.0) at 6
months follow-up in a comparable primary care study in
patients allocated to placebo treatment [25]. Half a stand-
ard deviation is considered to represent a clinically rele-
vant effect [26]. Our main hypothesis in this clinical
evaluation was that UCandAD by the PCP was as effective
(i.e. equivalent) in reducing depressive symptoms as
UCnoAD. This hypothesis was accepted if the 95% confi-
dence interval (CI) of the difference in improvement in
MADRS scores between UCandAD and UCnoAD at differ-
ent time points was between -5 and 5.
Statistical analysis
Using the sample size calculation of Jones et al for equiv-
alence trials [27], based on 90% power (1-β) to detect a
clinically relevant difference in improvement of -5 points
on the MADRS (α = 0.05, two-sided), 84 patients were
required in each group.
To estimate the CIs for the mean difference between the
groups, we used parameter estimates of repeated measures
multilevel analysis in MLwiN [28]. This method is charac-
terized by an unrestricted repeated measurements design,
allowing all observations to be used. Multilevel analysis
was used for both the intention-to-treat analyses and the
per-protocol analyses. To study change in MADRS scores,
baseline measurements were used as a covariate as the
improvement in depressive symptoms may be different
for patients with higher versus lower MADRS baseline
scores. In all analyses, all available time points were ana-
lyzed simultaneously.
Additionally, an adjusted model was analyzed. We
adjusted for additional specialized help from mental
health services during the experimental period, which was
considered a co-intervention, to check the robustness of
our outcomes.
In equivalence trials it is recommended to perform a per-
protocol analysis in all cases; intention-to-treat analysis is
no longer considered conservative [27,29]. When equiva-
lence is demonstrated in both the intention-to-treat and
the per-protocol analysis, the evidence is considered to be
strongest. We performed both intention-to-treat and per-
protocol analysis. If equivalence of the two treatments
could not be established, we explored superiority of either
treatment. As intention-to-treat analyses has been recog-
nized as the most conservative strategy for superiority tri-
als to analyse data, we focused at the intention-to-treat
analysis. First statistical significance was explored (95% CI
< 0 or 95% CI > 0), then clinical superiority was explored
(95% CI < -5 or 95% CI > 5).
In the intention-to-treat analyses all patients were ana-
lyzed according to group assignment. Per-protocol analy-
ses were performed for patients who received at least 70
defined daily doses (DDDs) of an antidepressant drug in
the first 3 months when in the UCandAD group, and
patients who received no more than 30 DDDs of an anti-
depressant drug in the first 3 months when in the
UCnoAD group. Thus, protocol violation has a different
meaning in the treatment groups; violators in the UCan-
dAD group received a less extensive treatment (no antide-
pressants), whereas violators in the UCnoAD group
received a more intensified treatment (additional antide-
pressants).
Differences in protocol violation between treatment
groups were analyzed using the chi-square test (SPSS
11.0). To find predictors of protocol violation logistic
regression was used for each treatment group separately.
The influence of gender, age, the presence of life events,
duration and history of depressive symptoms, chronic dis-
eases, neuroticism, severity of depression diagnosis at
baseline (i.e. minor versus mild-major depression, as
assessed by the PCP), and use of mental health services
during the first 3 months were explored.
In addition, some explorative analyses were performed.
Differences in benzodiazepines prescription between
treatment groups and differences in protocol violation in
combination with patient's treatment preferences and
assignment were analyzed using the chi-square test in
SPSS 11.0 (SPSS Inc., Chicago, Il).
The secondary outcomes, the SF-36 and the CSQ-8, were
explored for statistical significant differences in the inten-Page 4 of 11
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Flow chart of patients through trialigure 1
Flow chart of patients through trial. MADRS, Montgomery Åsberg Depression Rating Scale.
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MLwiN [28] for the SF-36. For the CSQ-8, total mean item
scores were computed and the t statistic in SPSS 11.0 was
used (two-sided, p < 0.05).
Results
Patients
Patients were recruited from February 2002 to March
2003. Of 117 participating PCPs, 59 assessed 293 contact-
ing patients for eligibility. As a result, 181 patients were
randomly assigned to one of the two treatments (Figure
1). No differences in baseline sociodemographic and clin-
ical characteristics between the patients in the two treat-
ment conditions (Table 1) were found.
For 160 patients, self-report information and/or informa-
tion from the pharmacist on antidepressants during the
first 13 weeks could be used to determine whether
patients had or had not violated the treatment protocol.
For 21 patients the necessary information was incomplete
or missing and we contacted the PCP for information on
antidepressant prescription in order to decide whether
protocol violations had occurred.
At baseline, 43% of the patients had no preference for any
of the two treatments (77/181); 19% preferred UCandAD
(35/181), and 38% preferred UCnoAD (69/181). PCPs
registered their treatment preference at baseline in 79% of
the patients (143/181). In 52% of the cases the PCP did
not have any preference regarding the treatment (75/143);
in 34% of the cases the PCP preferred UCandAD (48/
143), and in 14% the PCP preferred UCnoAD (20/143).
Table 1: Baseline demographic, socioeconomic, and clinical characteristics of participants of each group. Values are numbers 
(percentages) of patients unless stated otherwise.
Baseline characteristic Usual care + paroxetine (n = 85) Usual care (n = 96)
Age (mean (SD)) 46 (16) 46 (16)
Women 62 (73%) 70 (73%)
Minor depression diagnosis PCP* 15 (18%) 16 (17%)
Major Depressive Disorder (CIDI)† 56 (68%) 59 (65%)
Mild 21 (26%) 15 (16%)
Moderate 17 (21%) 25 (27%)
Severe 18 (22%) 19 (21%)
Dysthymia (CIDI)† 14 (17%) 17 (19%)
Baseline MADRS‡ (Mean (SD)) 23.7 (10.4) 24.1 (10.7)
Private insurance 19 (22%) 20 (21%)
Dutch ethnic group 72 (85%) 80 (83%)
Partner 61 (72%) 58 (60%)
Higher education§ 20 (24%) 24 (25%)
Employed 53 (62%) 61 (64%)
Mental health care use 3 (3.1%) 2 (2.4%)
Neurotic (high)¶ 40 (47%) 48 (50%)
Chronic disease (≥ 1) 33 (39%) 31 (32%)
Life events (≥ 1)# 63 (74%) 69 (72%)
Duration depression > 3 months 52 (61%) 61 (64%)
History of depression 64 (75%) 78 (81%)
Treatment history of depression 38 (45%) 45 (47%)
Patient's treatment preference:
Usual care + paroxetine 16 (19%) 19 (20%)
Usual care 30 (35%) 39 (41%)
No preference 39 (46%) 38 (40%)
Physician's treatment preference:
Usual care + paroxetine 26 (31%) 22 (23%)
Usual care 6 (7%) 14 (15%)
No preference 32 (38%) 43 (45%)
No preference registered 21 (25%) 17 (18%)
*Three to four depressive symptoms correspond to minor depression, five to six to mild-major depression.
†Composite International Diagnostic Interview (CIDI) diagnosis of 173 patients were obtained (96%); 82 patients allocated to usual care + 
paroxetine, 91 patients allocated to usual care.
‡Montgomery Åsberg Depression Rating Scale.
§At least 11 years of education.
¶As measured with the Neuroticism Scale of the NEO-FFI. A scale score of ≥ 40 was considered high, < 40 as low (range 12–60, median was 40).
#As measured with a translated and, with permission of the author, adapted version of the List of Threatening Experiences Questionnaire (LTE-Q).Page 6 of 11
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The mean number of consultations with the PCP in the
first 3 months, ascribable to our study, was 3.0 (SD 1.4),
and each lasted on average 15.1 min (SD 0.7) with no dif-
ferences between UCandAD (mean 3.1; SD 1.3) and
UCnoAD (mean 2.9; SD 1.4). During these consultations,
the PCP evaluated the depressive symptoms (82%), dis-
cussed the course of the depressive symptoms (76%), and
talked with the patient about their functioning at home or
at work (80%). Slightly less attention was paid to patient
education on depression (58%), emotional support
(71%), giving practical advice (64%), and formulating
achievable goals (55%). In patients receiving UCandAD,
the PCP also paid attention to the effects and side-effects
of antidepressants (62%), the prognosis as a result of anti-
depressant use (54%), and the importance of compliance
with the antidepressant therapy (57%). A total of 41
patients (23% of 181 patients) received additional spe-
cialized help from mental health services during the
experimental period; 15 in the UCandAD group and 26 in
the UCnoAD group (p > 0.05). For 127 patients (70% of
181), information on the prescription of benzodiazepines
was available. A total of 43 patients received additional
benzodiazepines; 19 in the UCandAD group and 24 in the
UCnoAD group (p > 0.05).
Primary outcome: MADRS
Table 2 presents the change in the severity of the depres-
sive symptoms and 95% CIs for both treatment groups
over 52 weeks. The results of Table 2 are visualized in Fig-
ure 2. As randomization had been successful (Table 1) we
did not explore potential effect modifiers or confounders.
Table 3 shows that additional specialized help from men-
tal health services during the first 3 months biased the
results to no difference (e.g. adjusted 95% CI at 6 weeks -
5.5 to 2.1 versus unadjusted 95% CI at 6 weeks -4.5 to 2.4
in the per-protocol analyses).
Findings
Table 2 shows that, in the intention-to-treat (n = 181) as
well as the per-protocol analysis (n = 133), equivalence of
UCandAD and UCnoAD could be demonstrated at 6
Differences between treatment groups in Montgomery Åsberg Depression Rating Scale (MADRS) scores, in relation to equiva-lenceFigu  2
Differences between treatment groups in Montgomery Åsberg Depression Rating Scale (MADRS) scores, in 
relation to equivalence. Schematic presentation. Horizontal bars indicate two-sided 95% confidence intervals (CIs). Blue 
tinted area indicates zone of equivalence. Bars a and b: The 95% CI of the difference in symptom change lies between the 
equivalence margins of -5 and 5 points difference; equivalence of both treatments is demonstrated. Bars f and h: The 95% CI of 
the difference in symptom change lies entirely to the left of zero; a statistical significant difference in favor of usual care + par-
oxetine is demonstrated.
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ment in MADRS scores between the treatment groups lies
between the equivalence margins of -5 and 5). However,
at 13, 26, or 52 weeks follow-up equivalence could not be
demonstrated.
Superiority of either treatment could not be demon-
strated; no statistical significant difference in effectiveness
of either treatment could be demonstrated at any time
point in the intention-to-treat analysis.
Protocol violations
Protocol violations more often occurred in UCandAD (30
of 85 patients) than in UCnoAD (18 of 96 patients) (p <
0.02). Specialized help from mental health services at 13
weeks (p < 0.01) predicted protocol violations in UCan-
dAD. Chronic disease (p = 0.04) and specialized help
from mental health services at baseline (p < 0.02) were
predictors of protocol violation in UCnoAD. Explorative
analyses showed that patients who preferred UCnoAD
violated the protocol more often when assigned to UCan-
dAD than when assigned to UCnoAD (number of viola-
tions 11/30 vs 5/39, p = 0.02). Patients who had no
treatment preference had comparable results (number of
violations 16/39 vs 5/38, p < 0.01). Patients who pre-
ferred UCandAD violated the protocol more often when
assigned to UCnoAD than when assigned to UCandAD
(number of violations 8/19 vs 3/16, p value not signifi-
cant).
To get an impression of the effect of protocol adherence
on the MADRS scores, the intention-to-treat analyses were
compared with the per-protocol analyses. The only
patients for whom marked differences were found, were
those with mild-major (instead of a minor) depression, as
diagnosed by the PCP. Patients receiving UCandAD who
were diagnosed with a mild-major depression had overall
lower mean MADRS scores in the per-protocol analysis
(mean difference -2.9 in the per-protocol analysis, versus
1.2 in the intention-to-treat analysis).
Patient's treatment preferences
Explorative analyses showed that patient's treatment pref-
erences were related to MADRS scores at 13 weeks and 26
weeks follow-up in the intention-to-treat analysis. At 13
weeks, patients who preferred UCandAD or UCnoAD and
received their preferred treatment had lower MADRS
scores. When the patient's preference for UCnoAD was in
line with the PCP's preference and with treatment assign-
ment, the positive effect increased (mean UCandAD 15.3;
SD 13.9 and UCnoAD 12.1; SD 7.7 vs overall mean UCan-
dAD 13.7; SD 11.1 and mean UCnoAD 15.7; SD 12.3). At
Table 2: Main outcome table. Baseline Montgomery Åsberg Depression Rating Scale (MADRS) scores and change in the depressive 
symptoms over 52 weeks for patients in the intention-to-treat and per-protocol analysis. Values are means unless stated otherwise. 
Estimated mean differences and 95% Confidence Intervals (CIs) are presented.
Intention-to-treat MADRS (n = 181)
Usual care + paroxetine (n = 85) Usual care (n = 96) Mean difference* SD 95% CI
Baseline score 23.7 24.1
6 weeks – baseline† -7.6 -6.0 -1.6 20.2 -4.7; 1.4‡
13 weeks – baseline † -10.2 -8.7 -1.5 22.5 -5.1; 1.9
26 weeks – baseline † -13.0 -10.0 -3.0 21.3 -6.4; 0.3
52 weeks – baseline † -14.7 -12.6 -2.1 24.1 -6.1; 1.9
Per-protocol MADRS (n = 133)
Usual care + paroxetine (n = 55) Usual care (n = 78) Mean difference* SD 95% CI
Baseline score 25.1 24.1
6 weeks-baseline† -7.8 -6.7 -1.1 20.0 -4.5; 2.4‡
13 weeks-baseline† -12.1 -9.0 -3.1 20.7 -6.8; 0.5
26 weeks-baseline† -13.9 -9.3 -4.6 20.6 -8.4; -0.9§
52 weeks-baseline† -17.6 -12.6 -5.0 21.2 -9.1; -1.0§
*A negative mean difference is a difference in favor of usual care + paroxetine.
†A negative score means a decrease in the severity of symptoms.
‡The 95% CI of the difference in symptom change lies entirely between the equivalence margins of -5 and +5 points, indicating equivalence of usual 
care + paroxetine and usual care.
§The 95% CI of the difference in symptom change lies entirely to the left of zero, indicating statistical significant differences in favor of usual care + 
paroxetine.Page 8 of 11
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had lower MADRS scores (mean UCandAD 11.0; SD 11.4
and UCnoAD 10.2; SD 9.4 vs overall mean UCandAD
11.3; SD 10.7 and mean UCnoAD 14.0; SD 11.8). No rela-
tion between patients' treatment preferences and MADRS
scores was found in the per-protocol analysis.
Secondary outcomes
SF-36
No significant differences on the PCS scale or the MCS
scale (SF-36) between the treatment groups were found at
any time point. For example, the mean score on the PCS
scale at 13 weeks follow-up was 43.8 (SD = 8.0) in UCan-
dAD and 46.1 (SD = 7.9) in UCnoAD. The mean score on
the MCS scale at 13 weeks follow-up was 40.5 (SD = 11.0)
in UCandAD and 37.8 (SD = 11.6) in UCnoAD.
CSQ-8
At 13 weeks follow-up, but not at 52 weeks, patients allo-
cated to UCandAD were modestly more satisfied with
their treatment than patients allocated to usual care alone
(mean item difference 0.18; p = 0.04).
Discussion
We conducted a large, pragmatic randomized equivalence
trial with 52 weeks follow-up in primary care patients
with minor and mild-major depression. We compared
usual care with antidepressants (UCandAD) to usual care
without antidepressants (UCnoAD) and hypothesized
that they were equally effective, i.e. equivalent. The results
showed that equivalence of UCandAD and UCnoAD was
demonstrated after 6 weeks of treatment in both the
intention-to-treat analysis and the per-protocol analysis.
Equivalence could not be demonstrated from 13 weeks
on. Therefore, one of the two treatments could be more
effective from 13 weeks on. We took the next step and
explored whether UCandAD was more effective than
UCnoAD. No statistical significant differences were found
between the treatments in the intention-to-treat analysis.
In summary, from 13 weeks on, there is no hard evidence
that both treatments are equally effective, but neither that
antidepressant medication adds substantial effectiveness
to usual care alone.
No differences between treatment groups in the physical
and mental functioning were found. Patients allocated to
UCandAD were more satisfied with their treatment in the
short run (at 13 weeks follow-up) than patients allocated
to UCnoAD. However, differences were small.
Are there no indications that antidepressants might have
some additional effectiveness over usual care alone? Fig-
ure 2, which visualizes the results of Table 2, suggests that
there are on average small differences between the treat-
ments in favour of UCandAD. In the per-protocol analysis
statistical significant differences between the treatment
groups were found at 26 and 52 weeks follow-up. Despite
the initial lack of benefit of antidepressant medication,
Table 3: Baseline Montgomery Åsberg Depression Rating Scale (MADRS) scores and change in the depressive symptoms over 52 
weeks for patients in the intention-to-treat and per-protocol analysis. Results are adjusted for additional specialized help from mental 
health services during the first 3 months. Values are means unless stated otherwise. Estimated mean differences and 95% CIs are 
presented.
Intention-to-treat MADRS (n = 181)
Usual care + paroxetine (n = 85) Usual care (n = 96) Mean difference* SD 95% CI
Baseline score 23.8 24.2
6 weeks – baseline† -7.7 -5.8 -1.9 20.7 -5.0; 1.2
13 weeks – baseline † -10.9 -8.4 -2.5 23.4 -6.1; 1.1
26 weeks – baseline † -13.1 -10.1 -3.0 21.4 -6.4; 0.3
52 weeks – baseline † -14.8 -12.7 -2.1 24.2 -6.2; 1.9
Per-protocol MADRS (n = 133)
Usual care + paroxetine (n = 55) Usual care (n = 78) Mean difference* SD 95% CI
Baseline score 25.2 24.1
6 weeks-baseline† -8.2 -6.5 -1.7 22.1 -5.5; 2.1
13 weeks-baseline† -13.3 -8.7 -4.6 24.3 -8.9; -0.3‡
26 weeks-baseline† -14.0 -9.3 -4.8 20.6 -8.5; -1.0‡
52 weeks-baseline† -17.7 -12.5 -5.2 21.2 -9.2; -1.2‡
*A negative mean difference is a difference in favor of usual care + paroxetine.
†A negative score means a decrease in the severity of symptoms.
‡The 95% CI of the difference in symptom change lies entirely to the left of zero, indicating statistical significant differences in favor of usual care + 
paroxetine.Page 9 of 11
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until the last follow-up assessments at 52 weeks, long after
the treatment had ended. Therefore, it is not very likely
that this effect was purely due to a placebo effect. These
outcomes should be weighted carefully, as they differ
from the results of the intention-to-treat analysis and pro-
tocol violation more often occurred in UCandAD. How-
ever, given the heterogeneity of depressive disorders,
some subgroups of patients may actually benefit from
antidepressants. We found an indication that in particular
patients with mild-major (instead of minor) depression
may benefit from additional antidepressant medication.
A recent review on the treatment of depression in primary
care concluded that patients with strong preferences, in
particular when psychotherapy is preferred, are likely not
to enter randomized clinical trials if their preferences are
not supported [30]. We also found some support for this
phenomenon. Because of the randomization procedure,
42 patients choose not to enter our trial. Furthermore, we
found that protocol violation more often occurred in
UCandAD. Patients who were not assigned to the treat-
ment of their preference were less compliant. This was
found in particular for patients who preferred UCnoAD or
had no treatment preference, but were assigned to UCan-
dAD. The review also concluded, based on results of par-
tially randomized patient-preference trials, that there is no
evidence that patient's treatment preference predicts clin-
ical outcome. However, our results indicate that patient's
treatment preferences were positively related to clinical
outcome, again in particular for patients who preferred
and were assigned to UCnoAD.
Our study had some limitations. The combination of a
pragmatic and an equivalence trial turned out to be diffi-
cult. Comparison of the unadjusted results in Table 2 and
the adjusted results in Table 3 show that co-interventions
have diluted differences between treatment groups. More-
over, more than 25% of the patients were not treated
according to the protocol (Figure 1). Protocol violations
reduce the contrast between the treatments. This is consid-
ered a problem in equivalence trials, because it increases
the risk of erroneously concluding equivalence (type I
error) [29,31]. However, in pragmatic trials, as in everyday
practice, protocol violations are common practice. Proto-
col violations therefore determine the effectiveness of an
intervention under normal circumstances.
There are very few controlled trials in primary care exam-
ining the effectiveness of antidepressant treatments for
minor and major depression, and these were designed to
prove superiority of antidepressants over placebo or prob-
lem solving treatment [32-36]. None of these studies
could prove superiority of antidepressant medication.
These results raise questions how liberal physicians
should be in prescribing antidepressants to patients in pri-
mary care [37]. Our study is the first equivalence trial on
the treatment of depression in primary care, while at the
same time the follow-up in our trial was much longer than
in most antidepressant studies in primary care. Added to
the fact that it was a pragmatic trial, mirroring normal
clinical practice, the generalizability is high.
Conclusion
Usual care combined with paroxetine (UCandAD) was as
effective as (equivalent to) usual care alone (UCnoAD)
over the first 6 weeks, but not thereafter. We found small
differences in effectiveness in favor of UCandAD, but
superiority was not demonstrated. We cannot but con-
clude that the question 'Do antidepressants add any effec-
tiveness to usual care?' remains open. We recommend
future studies to distinguish between subgroups of
patients who might benefit from antidepressant medica-
tion. Until then, the potential benefits of adding an anti-
depressant to usual care alone must be balanced
judiciously against possible harms such as side effects and
dependence. Moreover, patients should be properly
informed about the advantages and disadvantages of
interventions in order to enable them to make a balanced
choice.
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